Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Diagnostics - The Untold Story

Is Hologic Stock Outperforming the Dow?

Although Hologic has exceeded the Dow over the past year, analysts remain cautious about the stock’s prospects.

Is Wall Street Bullish or Bearish on Hologic Stock?

Is Wall Street Bullish or Bearish on Hologic Stock?

Though Hologic has outperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition

Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition

Rumours fly that Abbott is very close to sealing the deal to acquire cancer treatment champion Exact Sciences.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Is Co-Diagnostics Stock Sinking Tuesday?

Co-Diagnostics, Inc. (NASDAQ:CODX) shares plunged over 50% on Tuesday after the company announced a $7 million direct offering and a new Saudi-based joint venture.

Co-Diagnostics Stock Is Rocketing Higher Monday: What's Going On?

Co-Diagnostics, Inc. (NASDAQ:CODX) shares are trading higher Monday after the company signed a definitive agreement with Arabian Eagle to establish CoMira Diagnostics and localize its Co-Dx PCR platform across the Middle East.

Revvity Lifts Profit Outlook, Launches $1 Billion Buyback Plan

Revvity, Inc. (NYSE:RVTY) announced its third-quarter 2025 financial results on Monday. The company’s performance was mixed compared to analyst expectations, and the stock declined immediately.

EXCLUSIVE: Co-Diagnostics Inks JV With Saudi Arabia Firm For Middle East Market

Co-Diagnostics, Inc. (NASDAQ:CODX) announced on Monday that it has entered into a joint venture agreement with the Kingdom of Saudi Arabia (KSA) based Arabian Eagle Manufacturing.

inkl

Read news from The Economist, FT, and more,
with one subscription

Quest Diagnostics Reports Q3 Earnings, Shares Slide

Quest Diagnostics Reports Q3 Earnings, Shares Slide

Shares of Quest Diagnostics (NASDAQ:DGX) are falling Tuesday after the medical laboratories company shared mixed earnings results.

Co-Diagnostics Stock Plunges 28% In Pre-Market Despite Strategic Saudi Partnership

Co-Diagnostics Stock Plunges 28% In Pre-Market Despite Strategic Saudi Partnership

Co-Diagnostics Inc. (NASDAQ:CODX) shares dropped 28.26% to $0.46 in pre-market trading on Tuesday, wiping out the gains from Monday’s 80.76% surge, which had closed at $0.64, according to Benzinga Pro data.

This Quest Diagnostics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

This Quest Diagnostics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity

Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity

Quest Diagnostics Inc (NYSE:DGX) may be encountering what you might call a post-earnings digestion dance. Initially, DGX stock jumped higher, perhaps due to the algorithms and retail traders responding in unison to the better-than-expected results for the second quarter. But the next day, the security slipped, possibly as fund managers…

Bargain-Hunting: 3 Mega-Cap Pharmaceutical Stocks to Buy and Hold

Bargain-Hunting: 3 Mega-Cap Pharmaceutical Stocks to Buy and Hold

Although the heightened market volatility has caused several pharma stocks to slump in price, the sector’s long-term prospects look bright. This sector has been attracting massive investments and could remain in the limelight in the near term. So, we think it should be wise to buy and hold mega-cap pharmaceutical…

Co-Diagnostics Stock Surges As Q1 Results Surpass Street Expectations

Co-Diagnostics Stock Surges As Q1 Results Surpass Street Expectations

Co-Diagnostics Inc (NASDAQ: CODX) reported first-quarter revenue growth of 13.4% year-over-year to $22.7 million, beating the consensus of $20.17 million.

5 Healthcare Stocks Likely to Withstand a Recession

5 Healthcare Stocks Likely to Withstand a Recession

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

Get all your
news in one place.

100's of premium titles.
One news app.

Co-Diagnostics's Earnings Outlook

Co-Diagnostics (NASDAQ:CODX) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that Co-Diagnostics will report an earnings per share (EPS) of $0.12.

Why Co-Diagnostics Shares Are Trading Higher Today

Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher Tuesday after the company announced its board authorized a share repurchase program, allowing Co-Diagnostics to repurchase up to $30 million of its common stock.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Abbott Laboratories

Medical – Pharmaceuticals

Quest Diagnostics

Novo Nordisk AS

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

363,594 stories

the Middle East

the Kingdom of Saudi Arabia

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play